Summary: Researchers demonstrated that targeted antioxidant therapy can bypass the neurodevelopmental deficits caused by 22q11.2 deletion syndrome without correcting the underlying genetic mutation itself.
The study used a mouse model of 22q11.2 deletion syndrome, the second most common microdeletion in humans and a major genetic risk factor for schizophrenia and autism spectrum disorder. The team identified mitochondrial oxidative stress as a driver of abnormal dendritic growth and synaptic connectivity.
Administering N-acetyl cysteine (NAC) mitigated this oxidative burden, improving mitochondrial health and restoring dendritic arborization. Critically, rather than restoring original gene expression, NAC activated an alternative network of compensatory genes, enabling neurons to form functional neural circuits and improve cognitive performance.
Key Facts
- Mechanistic Bypass Strategy: The study proves that neurodevelopmental disorders caused by genetic deletions can be treated by activating secondary, compensatory gene networks rather than restoring baseline expression of the deleted genes.
- Mitochondrial Oxidative Stress: Researchers identified elevated reactive oxygen species and mitochondrial dysfunction as key drivers of impaired dendritic branching and circuit formation in 22q11.2 deletion models.
- Efficacy of N-Acetyl Cysteine (NAC): Treatment with the blood-brain barrier-permeable antioxidant NAC restored mitochondrial health, promoted dendritic arborization, and boosted synaptic signal transmission.
- Behavioral Circuit Recovery: Strengthening existing synaptic connections in the NAC-treated mouse models led to measurable performance improvements on behavioral tasks assessing learning and cognitive flexibility.
- Clinical Translation Blueprint: 22q11.2 deletion syndrome affects 1 in 2,000 to 4,000 live births. This compensatory genetic approach offers a potential paradigm shift for treating complex microdeletion syndromes where direct gene editing remains challenging.
Source: Virginia Tech
Scientists at the Fralin Biomedical Research Institute at VTC have discovered how an experimental therapy can help brain cells overcome the effects of a disease-causing genetic deletion. Instead of repairing the deletion and its immediate consequences, the therapy redirects brain development by helping at-risk neurons grow and connect more normally.
The findings, published in Disease Models & Mechanisms, suggest that some genetic brain disorders may be treated by targeting the cellular mechanisms disrupted by a genetic change rather than repairing the genetic change itself.
The research focused on 22q11.2 deletion syndrome, the second most common genetic deletion disorder and among the strongest known genetic risk factors for schizophrenia in humans. The syndrome affects approximately one in every 2,000 to 4,000 births and is also associated with autism spectrum disorder and a range of cognitive and developmental challenges.
Using a mouse model of 22q11.2 deletion syndrome, the researchers identified oxidative stress — a buildup of harmful oxygen-containing molecules inside brain cells — as a key contributor to abnormal brain development.
They then treated mice with N-acetyl cysteine (NAC), an antioxidant that effectively crosses the blood-brain barrier, to determine whether reducing that stress could restore healthy growth and connectivity.
The treatment improved the health of mitochondria, strengthened connections between neurons, and restored the growth of dendrites — the branch-like extensions on neurons that receive synaptic signals from other neurons, mediating communication within the brain’s neural networks.
“Think of it as a detour around a network of winding roads where several trees have fallen,” said Anthony-Samuel LaMantia, professor at the Fralin Biomedical Research Institute at VTC and the study’s corresponding author. “The detour still gets you to your destination even though the original route remains blocked. In this case, the therapy activates a different set of genes that helps neurons form functional brain circuits despite the genetic deletion.”
The researchers discovered that the therapy did not restore the activity of genes disrupted by the deletion. Instead, it activated a different network of genes that enabled neurons to achieve many of the same developmental results.
“That was surprising because the assumption behind most therapies is that you have to restore gene expression to its normal ground state,” said LaMantia, who is the director of the institute’s Center for Neurobiology Research. “Our findings suggest that may not always be possible or even necessary. There can be therapeutic benefits from taking an alternate route.”
The study also helps explain why the therapy improves brain function. Rather than replacing lost neurons, the treatment strengthened the connections among the neurons that remained, restoring the cumulative strength of communication signals within brain circuits that underlie learning and cognitive flexibility.
In the mouse model, these improvements were accompanied by better performance on behavioral tasks that depend on those circuits.
Although additional research will be needed before the findings can be translated into human therapies, the study points to a new way of thinking about treatments for genetic brain disorders, LaMantia said. Rather than trying to correct every disrupted gene or molecular pathway, researchers may be able to harness the natural ability of gene networks to help brain cells develop more normally.
“Gene networks are remarkably flexible,” LaMantia added. “We may be able to develop therapies that engage that flexibility instead of trying to correct a specific genetic or molecular disruption that may be too difficult to manipulate directly.”
The study was led by LaMantia with colleagues Shah Rukh, Daniel Meechan, Abra Roberts, Connor Siggins, Zachary Erwin, and Thomas Maynard of the Fralin Biomedical Research Institute. LaMantia is also a professor in the Department of Biological Sciences of the College of Science.
Key Questions Answered:
A: 22q11.2 deletion syndrome is a genetic disorder caused by a missing piece of chromosome 22, occurring in 1 in 2,000 to 4,000 births. It is one of the strongest known genetic risk factors for developing schizophrenia and is frequently associated with autism spectrum disorder and developmental delays.
A: NAC crosses the blood-brain barrier and reduces oxidative stress within mitochondria. Instead of turning the deleted genes back on, NAC triggers a different network of compensatory genes that promotes normal dendritic growth, strengthens synaptic connections, and restores neural circuit function.
A: Traditional therapeutic models assume that a missing or mutated gene must be directly corrected to restore function. This study demonstrates that engaging the natural flexibility of secondary gene networks can achieve the same structural and behavioral recovery without needing to modify the primary genetic defect.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this genetics and neurodevelopment research news
Author: John Pastor
Source: Virginia Tech
Contact: John Pastor – Virginia Tech
Image: The image is credited to Neuroscience News
Original Research: Open access.
“An antioxidant therapy elicits distinct transcriptome responses in 22q11-deleted upper layer cortical projection neurons” by Shah Rukh, Daniel W. Meechan, Abra Roberts, Connor Siggins, Zachary D. Erwin, Thomas M. Maynard, Anthony-S. LaMantia. Disease Models & Mechanisms
DOI:10.1242/dmm.052786
Abstract
An antioxidant therapy elicits distinct transcriptome responses in 22q11-deleted upper layer cortical projection neurons
We characterized in vitro and in vivo responses to the antioxidant N-acetyl cysteine (NAC), which in the 22q11.2 Deletion Syndrome LgDel mouse model restores growth and connectivity of developing upper layer cortical projection neurons (Layer 2/3 PNs) and improves cognitive performance.
NAC ameliorates L 2/3 PN developmental pathology without restoring wild type (WT) growth patterns or expression levels of downstream targets of 22q11-deleted genes. Instead, novel neuronal growth and antioxidant defense genes are differentially expressed compared to LgDel or WT: some generally NAC-regulated, others responsive only in the context of 22q11 deletion.
NAC also elicits novel growth and antioxidant defense gene expression in differentiating 22q11-deleted L 2/3 PNs in postnatal LgDel mouse cortex rather than restoring 22q11 downstream targets to WT levels; however, these L 2/3 PN-selective in vivo changes differ substantially from those in primary culture.
Thus, the NAC therapeutic response that diminishes oxidative stress-related L 2/3 PN developmental circuit and behavioral pathology due to 22q11 deletion has a distinct in vivo signature.
